NextCure, Inc. (NXTC)
Largest Insider Buys in Sector
NXTC Stock Price History Chart
NXTC Stock Performance
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; …
Insider Activity of NextCure, Inc.
Over the last 12 months, insiders at NextCure, Inc. have bought $0 and sold $0 worth of NextCure, Inc. stock.
On average, over the past 5 years, insiders at NextCure, Inc. have bought $5.51M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $5.51M was made by Sofinnova Venture Partners IX, L.P. (10 percent owner) on 2019‑11‑15.
List of Insider Buy and Sell Transactions, NextCure, Inc.
| 2019-11-15 | 10 percent owner | 150,000 0.9742% | $36.75 | $5.51M | -7.91% | |||
| 2019-05-13 | 700,000 4.0096% | $15.00 | $10.5M | +82.16% | ||||
| 2019-05-13 | director | 350,000 2.0048% | $15.00 | $5.25M | +82.16% | |||
| 2019-05-13 | 10 percent owner | 400,000 2.2912% | $15.00 | $6M | +82.16% | |||
| 2019-05-13 | director | 50,000 0.2864% | $15.00 | $750,000 | +82.16% | |||
| 2019-05-13 | 10 percent owner | 50,000 0.2864% | $15.00 | $750,000 | +82.16% | |||
| 2019-05-13 | director | 125,000 0.716% | $15.00 | $1.88M | +82.16% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 2711013 9.6906% | $1.29 | 1 | 0 | ||
| Khuong Chau Quang | director | 2711013 9.6906% | $1.29 | 1 | 0 | |
| Sofinnova Venture Partners IX, L.P. | 10 percent owner | 2671856 9.5506% | $1.29 | 2 | 0 | <0.0001% |
| SHANNON TIMOTHY M | director | 2254442 8.0585% | $1.29 | 1 | 0 | |
| CANAAN X L.P. | 10 percent owner | 2254442 8.0585% | $1.29 | 1 | 0 |
Institutional Investor Ownership
| Sofinnova | $5.96M | 9.55 | 2.67M | 0% | +$0 | 0.01 | |
| Logos Global Management Lp | $4.29M | 6.88 | 1.93M | New | +$4.29M | 0.46 | |
| Affinity Asset Advisors | $3.03M | 4.86 | 1.36M | New | +$3.03M | 0.05 | |
| OrbiMed | $2.54M | 4.08 | 1.14M | -57.91% | -$3.5M | 0.02 | |
| Millennium Management LLC | $2.53M | 4.05 | 1.13M | -0.55% | -$14,073.53 | <0.01 |